molecules transparent


Registration is now open!

Explore how cutting-edge technology and developments in molecular testing and diagnostics continue to have a major impact on patient care.

Registration Fees​

Early Bird Rate Until March 25, 2024 Regular Rate From March 26, 2024
Delegate, AMP Member 530,00 € 670,00 €
Delegate, AMP Affiliate Society 570,00 € 740,00 €
Delegate, Non-AMP Member 620,00 € 780,00 €
Medical/ Technical Assistant (MTA) 470,00 € 530,00 €
Student/Trainee* 270,00 € 345,00 €

*Student/Trainee: A delegate who is a student, resident or fellow. AMP Membership is free for Trainees (join here.) A letter from the Program Director is required for Trainees who are not AMP Associate members and must be submitted at the time of registration.

Your registration includes:

  • Admission to scientific sessions
  • Admission to poster exhibition
  • Industry sponsored sessions
  • Congress documents
  • Admission to the opening ceremony and networking reception
  • Access to online abstracts after the congress
Save up to €100 on registration and become part of the AMP Community! Take advantage of the benefits of becoming a member. To become a member, click here

Invitation letter

If your nationality is listed in the following link, you will require a visa to enter Spain (
The visa invitation letter will only be sent to participants who have paid their registration fee. Please provide the following information by e-mail in order to receive your visa invitation letter:

  • Full Name
  • Passport No.
  • Expiry Date
  • Country of Origin
  • Date of Birth
  • Registration ID
If you require an official invitation letter stating your registration to AMP Europe 2024 for visa purposes, please contact us

Federico Monzon

Federico A. Monzon is a molecular pathologist with extensive experience translating novel genomic technologies into clinical molecular tests, including leading studies on prostate and renal cancer genomics and the validation of one of the first FDA-cleared gene expression clinical assays for the diagnosis of tumors of unknown origin while at the University of Pittsburgh and Houston Methodist Hospital. At Invitae and Baylor Genetics laboratories, he pioneered the use of panel testing for hereditary cancers as well as cancer exome sequencing.

Dr. Monzon is a consultant on medical and scientific strategy for companies in the diagnostic space. Currently, he is Chief Medical Officer (CMO) at Delphi Diagnostics, a laboratory focused on providing genomic tools for the management of breast cancer patients. Prior to that, he served as CMP for Castle Diagnostics and served as Medical Director of Oncology and Medical Director for Latin America at Invitae Corporation. Previously, Dr. Monzon served as Director of Pathology at the Cancer Genetics Laboratory at Baylor College of Medicine. He earned his M.D. from the Universidad Nacional Autónoma de México (UNAM) and is board-certified by the American Board of Pathology in anatomic, clinical and molecular genetic pathology. Dr Monzon was the 2017 President of the Association for Molecular Pathology (AMP) and continues to be engaged in AMP and other professional societies to shape the future of clinical genomic medicine.